> 首页 > 产品 > 一抗 > 其他 > Anti-CTLA4 & PD-1 Reference Antibody (Volrustomig)

Anti-CTLA4 & PD-1 Reference Antibody (Volrustomig)

Anti-CTLA4 & PD-1 Reference Antibody (Volrustomig) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-CTLA4 & PD-1 Reference Antibody (Volrustomig) is 98.99%, determined by SEC-HPLC.
Volrustomig bound to CTLA4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Volrustomig bound to huCTLA4-His, and the EC50 was 0.008 nM.
Volrustomig bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Volrustomig bound to hu-PD-1-His, and the EC50 was 0.006 nM.
Volrustomig bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Volrustomig bound to huPD-1-Jurkat cells, and the EC50 was 2.279 nM.
Volrustomig bound to huCD40-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Volrustomig bound to huCD40-CHO-K cells, and the EC50 was 8.874 nM.
Co-incubation of Volrustomig with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Volrustomig was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 6.643 nM.
The detected molecular weight of Anti-CTLA4 & PD-1 Reference Antibody (Volrustomig) is 146.51 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P16410 & Q15116
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	CTLA-4 / CD152,PDCD1 / PD-1 / CD279
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.